## 1 Antidepressant and antipsychotic drug prescribing and complications of diabetes: a

## 2 systematic review of observational studies

- 3
- 4 Charlotte R L Greene<sup>1</sup>, Hanna Ward-Penny<sup>2</sup>, Marianna F Ioannou<sup>2</sup>, Sarah H Wild<sup>1</sup>, Honghan Wu<sup>1,3</sup>,
- 5 Daniel J Smith<sup>4</sup>, Caroline A Jackson<sup>1\*</sup>
- 6
- <sup>1</sup>Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG
- 8 <sup>2</sup>Edinburgh Medical School, University of Edinburgh, The Chancellor's Building, Edinburgh
- 9 Bioquarter, 49 Little France Crescent, Edinburgh, EH16 4SB
- <sup>3</sup>Institute of Health Informatics, University College London, 222 Euston Road, London, NW1 2DA
- <sup>4</sup>Centre for Clinical Brain Sciences, University of Edinburgh, The Chancellor's Building, Edinburgh
- 12 Bioquarter, 49 Little France Crescent, Edinburgh, EH16 4SB
- 13
- 14 \*Corresponding author:
- 15 Dr Caroline Jackson, <u>caroline.jackson@ed.ac.uk</u>, Tel: +44 (131) 6503223
- 16
- 17

18

Abstract

19	Aims
20	Psychotropic medication may be associated with adverse effects, particularly in people with
21	diabetes. We conducted a systematic review of observational studies investigating the association
22	between antidepressant or antipsychotic drug prescribing and diabetes outcomes.
23	Methods
24	We systematically searched PubMed, EMBASE, and PsycINFO to 15 <sup>th</sup> August 2022 to identify eligible
25	studies. We used the Newcastle-Ottawa scale to assess study quality and performed a narrative
26	synthesis.
27	Results
28	We included 18 studies, 14 reporting on antidepressants and four on antipsychotics. There were 11
29	cohort studies, one self-controlled before and after study, two case-control studies, and four cross-
30	sectional studies, of variable quality and highly heterogeneous in terms of study population,
31	exposure definition and outcome analysed. Antidepressant prescribing may be associated with
32	increased risk of macrovascular outcomes, whilst evidence on antidepressant and antipsychotic
33	prescribing and glycaemic control was mixed. Few studies reported on microvascular complications
34	and cardiometabolic factors other than glycaemic control and just one study reported on
35	antipsychotics and diabetes complications.
36	Conclusions
37	There has been little study of antidepressant and antipsychotic drug prescribing in relation to
38	diabetes outcomes. Further, more methodologically robust, research is needed to inform and
39	enhance antidepressant and antipsychotic drug prescribing and monitoring practices in people with
40	diabet es.
41	
42	Keywords: Diabetes mellitus; diabetes outcomes; diabetes complications; antidepressant

43 medication; antipsychotic medication; systematic review

## 44 **1.1 Introduction**

45	Antidepressant and antipsychotic drugs are common psychotropic medications used in treating
46	mental illness such as major depression, bipolar disorder, and schizophrenia [1, 2], with prescribing
47	having increased in high income countries in recent years [3, 4]. This may be partly driven by longer
48	treatment duration, but also by more frequent use, including for other indications (such as
49	agitation and aggression in autism spectrum disorder and dementia [5] and chronic pain, migraines,
50	and insomnia [6]). This increased use is of psychotropic drugs is of particular concern given that they
51	appear to be associated with risk factors for cardiovascular disease and type 2 diabetes such as
52	obesity, insulin resistance, and dyslipidaemia [7, 8], as well as major cardiovascular events such as
53	coronary heart disease and stroke [9, 10].
54	These adverse effects must be considered in the context of their use among people with diabetes,
55	including the bidirectional links between mental illness and diabetes [11] and the use of tricyclic
56	antidepressants (TCA) to treat neuropathic pain occurring as a complication of diabetes [12].
57	Previous reviews have summarised evidence from experimental studies on the effect of
58	antidepressants on cardiometabolic risk factors in people with diabetes [13, 14]. Although these
59	reviews concluded that some antidepressant subtypes may be associated with improved glycaemic
60	control, the overall evidence was inconclusive, in part due to low study quality, small sample sizes,
61	and insufficient follow-up to adequately investigate longer-term outcomes such as vascular
62	morbidity or mortality.
63	To our knowledge there is no previous systematic review of observational studies reporting the
64	association between antidepressant or antipsychotic drugs and diabetes outcomes. We therefore
65	conducted a systematic review of observational studies in people with diabetes that examined the
66	association between antidepressant or antipsychotic drug prescribing and clinical complications of
67	diabetes (including cardiovascular and microvascular morbidity), mortality, or cardiometabolic risk
68	factors.

69

## 70 2.1 Materials and methods

- 71 This review is reported in accordance with the PRISMA guidelines. The review protocol was not
- 72 registered

#### 73 **1.2.1** Data sources and searches

- 74 We searched PubMed, EMBASE, and PsycINFO from point of inception to August 15<sup>th</sup> 2022 using a
- 75 comprehensive electronic search strategy (Supplemental appendix 1).

## 76 **1.2.2 Study selection**

- 77 We included cohort, case-control, self-controlled or cross-sectional studies conducted among adults
- 78 with type 2 diabetes that examined the association between prescribing of any antidepressant
- and/or antipsychotic prescribing versus no prescribing in relation to diabetes outcomes
- 80 (macrovascular or microvascular complications; all-cause mortality; or cardiometabolic risk factors
- 81 [glycaemic control; blood pressure; or lipid levels]). See Supplemental Table 1 for a detailed
- 82 summary of the inclusion criteria. We did not limit our search to studies published in the English
- 83 language, but ultimately only included English language articles.
- 84 Two reviewers (CRLG and HWP or MFI and CAJ) independently screened titles and abstracts and the
- 85 full-text of potentially eligible articles and extracted information on study and population
- 86 characteristics, exposure and outcome/case definitions, statistical methods, and results from
- 87 included articles. Disagreements about suitability for inclusion or data extracted were resolved
- 88 through discussion with a third reviewer (CAJ or SHW).
- 89 **1.2.3 Quality assessment**
- 90 Two reviewers (CRLG and HWP or MFI and CAJ) assessed methodological study quality using the
- 91 Newcastle-Ottawa scale [15]. This assesses the quality of observational studies across eight items
- 92 within three domains: (i) the selection of the study groups; (ii) the comparability of the groups; (iii)
- 93 the ascertainment of either the outcome or exposure of interest, where relevant.
- 94 **1.2.4** Data synthesis and analysis

- 95 We performed a narrative synthesis since substantial clinical and methodological heterogeneity
- 96 between studies precluded meta-analysis.
- 97
- 98 3.0 RESULTS
- 99 **3.1 Study characteristics**
- 100 Our search yielded 11,216 articles, with 19 eligible articles representing 18 studies ultimately
- 101 included (Figure 1).
- 102 Study characteristics are described in Table 1. Details of the antidepressant and antipsychotic drugs
- 103 included with each study are given in Supplemental Table 2. Eleven studies were cohort [16-26], one
- 104 was a self-controlled before and after study [27], two were case-control [28, 29], and four were
- 105 cross-sectional studies [30-33]. Two studies included overlapping study populations [21, 27], but
- 106 adopted different study designs to address a similar question and so both were included in the
- 107 narrative synthesis. There was considerable heterogeneity between studies in terms of study
- 108 population, exposure definitions and outcomes analysed. All studies were from high-income
- 109 settings. Study populations were most frequently derived from people with newly diagnosed
- 110 diabetes in the general population. Two studies included a study population with comorbid mental
- illness and diabetes (one with depression [25] and one with schizophrenia [24]).
- 112 **3.2 Quality assessment**
- 113 Methodological study quality ranged from three to eight out of nine stars (Supplemental Table 3).
- 114 Concerns arising in some studies included: poor comparability due to insufficient adjustment for
- 115 relevant confounders including confounding by indication; use of self-report for exposure and/or
- 116 outcome assessment; poor representativeness of the population; low precision due to small sample
- 117 sizes; and no description of the response rate and/or attrition (where applicable).
- 118 **3.3** Antidepressant prescribing and diabetes outcomes
- 119 **3.3.1** Diabetes complications

120 Of 14 studies reporting on antidepressant prescribing, 8 reported associations with complications 121 (largely macrovascular) of diabetes, comprising 6 cohort studies [17-20, 25, 26] and two cross-122 sectional studies [30, 33] (Table 2 and Supplementary Table 4a). Outcomes were heterogeneous and 123 findings were mixed. 124 Receipt of antidepressant prescriptions, in comparison to no record of anti-depressant prescribing, 125 was associated with higher crude incidence of myocardial infarction (MI) [20] and of a composite 126 macrovascular outcome [25]. However, lack of adjustment for age, sex and other factors that may 127 differ between groups limits conclusions from these studies. A third cohort study found that 128 selective serotonin reuptake inhibitor (SSRI) antidepressant prescribing was associated with 129 increased risk of 30-day post-stroke mortality [26], with the excess risk greatest for people whose 130 SSRI prescription was initiated shortly before stroke. A cross-sectional study of older men of low-131 income from one treatment centre reported greater odds of a composite cardiovascular morbidity 132 outcome and of MI specifically in crude analyses without control of confounding factors [30]. In 133 contrast, a cohort study with a median of 9.6 years follow-up derived from post-hoc analyses of a 134 clinical trial for a weight loss intervention [19] reported that antidepressant prescribing was 135 associated with reduced cardiovascular morbidity or mortality in women, but not men. Risk of 136 peripheral artery disease was reported to be similar in those with diabetes prescribed versus not 137 prescribed antidepressants [18]. Finally, the only cohort study to describe microvascular 138 complications reported higher crude incidence of a composite microvascular outcome in people 139 prescribed anti-depressants among a Taiwanese cohort of people newly treated for diabetes [25], 140 whilst a small cross-sectional study of people with a diagnosis of diabetes or with HbA1c 6.5% who 141 took part in the National Health and Nutrition Examination Survey in the US found that self-reported 142 antidepressant was associated with lower odds of retinopathy compared to people not reporting 143 anti-depressant use after adjusting for sociodemographic and clinical characteristics [33] (Table 2). 144 Supplemental Table 5a includes details of additional results reported in some studies, including

145 investigations of variations of composite outcomes, interactions and associations by antidepressant

- 146 drug subtypes, with findings generally consistent with primary results.
- 147 **3.3.2 Glycaemic control**
- 148 Six studies reported on antidepressant prescribing in relation to glycaemic control [16, 21, 22, 27, 29,
- 149 31], with mixed findings. Of the three cohort studies, two reported no statistically significant
- 150 difference in the association between antidepressant prescribing and optimal glycaemic control [21,
- 151 22]. The third study reported that antidepressant use was associated with lower risk of sub-optimal
- 152 glycaemic control [16]. Interestingly, a pre-post study reported lower HbA1c levels following
- 153 antidepressant medication initiation [27]. One cohort study also reported that receipt of
- 154 antidepressants was associated with increased odds of prescribing of glucose lowering drugs (GLDs)
- 155 [21]. Similarly, a case-control study found that among people with newly diagnosed diabetes,
- 156 current receipt of SSRI antidepressant prescriptions was associated with a more than two-fold
- 157 increased risk of insulin prescription [29]. Similar associations were observed for other
- 158 antidepressant classes and for other durations, with no associations observed for past prescriptions
- 159 (Table 2). A cross-sectional study among people from low-income areas found that antidepressant
- 160 prescribing from multiple classes was associated with higher values of HbA1c, after adjustment for
- 161 depression severity [31], whereas there was no association between individual antidepressant class
- 162 prescribing and HbA1c levels.
- 163 **3.3.3 Lipid profile and lipid-lowering treatment**
- 164 One cohort study found that antidepressant prescribing was associated with abnormal lipid profiles
- 165 or receipt of lipid-lowering medication [22], whereas a second reported that antidepressant
- 166 prescribing may have a small protective effect on cholesterol levels [21], with findings broadly
- 167 consistent by prescription timing and across antidepressant subtypes (Supplemental Table 5a).
- 168 **3.4** Antipsychotic prescribing and diabetes outcomes
- 169 **3.4.1** Diabetes complications

170	Just four studies reported on antipsychotic prescribing in relation to diabetes outcomes. The two
171	studies that investigated the association between antipsychotic prescribing and clinical
172	complications of diabetes used population-based national registers [24, 32]. A cohort study of
173	people with schizophrenia found that, compared to no antipsychotic prescribing, regular
174	antipsychotic prescribing was associated with a 20% and 27% reduced risk of cardiovascular
175	morbidity, and all-cause mortality, respectively [24] (Table 3). There was no clear evidence of an
176	association between antipsychotics and microvascular complications. When stratifying by metabolic
177	risk of antipsychotics, the authors found that drugs considered to have an intermediate or high
178	metabolic risk were associated with a significantly reduced risk of all complications including
179	cardiovascular and microvascular morbidity (Supplemental Table 5b).
180	A second, cross-sectional, study found that the prevalence of retinopathy was lower in people who
181	had been prescribed antipsychotics for a total of more than 12 months than in a comparison group
182	matched for age, sex, diabetes type and duration, body mass index and smoking status that had not
183	been prescribed antipsychotics (Table 3) [32].
184	Two studies reported a link between that antipsychotic prescribing and poorer glycaemic control
185	[23, 28], and one reported the opposite finding [32]. The only cohort study [23] found that receipt of
186	antipsychotic prescriptions within the first two years of diabetes diagnosis was associated with a
187	two-fold increased risk of first insulin prescription, which attenuated to a 30% increased risk after
188	adjustment for other drug prescriptions (Table 3). In a case-control study of older adults, receipt of
189	an antipsychotic prescription in the previous 180 days was associated with an increased risk of
190	hospitalisation for hyperglycaemia, regardless of diabetes medication type [28]. This effect was
191	strongest among those receiving a first prescription of antipsychotics (Table 3) and consistent across
192	antipsychotic subtypes (Supplemental Table 4b). In contrast, a cross-sectional study found that mean
193	HbA1c values were significantly lower in people prescribed antipsychotics for more than 12 months
194	in total than in those who never received antipsychotics [32].
195	3.4.3 Other cardiovascular risk factors

196 Antipsychotic prescribing was also associated with significantly lower systolic and diastolic blood

197 pressure and total cholesterol although absolute differences were small (Supplemental Table 5b).

#### **4.1 DISCUSSION**

- 199 Our review revealed that few observational studies have investigated the association between
- 200 antidepressant and antipsychotic drug prescribing and diabetes outcomes. Studies of associations
- 201 with microvascular complications and cardiometabolic factors other than glycaemic control and the
- 202 association between antipsychotic prescribing and any diabetes complication were particularly
- 203 limited. The published studies are highly heterogeneous, particularly in terms of the study
- 204 population, exposure definitions, and outcomes. Lack of comparability and study shortcomings
- 205 highlight key gaps and limit conclusions. Tentative conclusions are that, among people with diabetes,
- antidepressant prescribing may be associated with an increased risk of cardiovascular morbidity or
- 207 mortality, and both antidepressant and antipsychotic prescribing may be linked to poorer glycaemic
- 208 control, but the evidence is very mixed.

#### 209 **4.1 Strengths and limitations**

- 210 To the best of our knowledge this is the first systematic review of observational studies reporting
- 211 associations between antidepressant or antipsychotic drug prescribing and complications, mortality,

212 or cardiometabolic risk factors in people with diabetes. Other strengths include our use of a detailed

213 and comprehensive search strategy applied to three bibliographic databases, independent screening

and data extraction by two reviewers, and assessment of study quality.

215 A limitation of this review is the exclusion of outcomes related to weight changes and obesity, that

216 have previously been linked to antidepressant and antipsychotic use [34, 35], as these outcomes

- 217 were beyond the scope of our review. Also beyond our scope were studies which reported on
- 218 progression of diabetes complications or compared prescribing of one psychotropic drug versus
- another. The latter is particularly important when investigating adverse effects of antidepressant
- and antipsychotic prescribing in people with SMI, where given the clinical need to prescribe,
- 221 comparison of type of medication becomes more important than comparison of use versus non-use.

222 We recommend that future reviews examine this topic in greater depth by focusing on study

- 223 populations with comorbid SMI and diabetes only.
- 224 Further limitations of this review reflect the limitations of existing studies. Many of these have
- insufficient control of confounding factors, including lifestyle behaviours, socioeconomic status, and
- 226 critically, confounding by indication, particularly for mental illness. It is difficult to estimate how the
- 227 latter might have affected estimates with potential bias in both directions. Mental illness is
- associated with higher risk of poor diabetes outcomes [36-38], partly through higher prevalence of
- 229 unhealthy lifestyle factors, including overweight/obesity, lower socioeconomic status [39], poorer
- treatment adherence, and in some settings, receipt of sub-optimal care [39]. Conversely, in other
- settings, people with comorbid mental illness and diabetes may be more likely than people with
- diabetes without mental illness to receive optimal routine monitoring of certain care indicators [40],
- perhaps due to more frequent visits to their primary care practitioner [41].
- 234 Although ascertainment of prescriptions through electronic records minimises information bias and
- 235 loss to follow-up, prescribing records do not reflect actual drug use. For studies where exposure
- 236 status was identified using interviews or assessment visits, this information may be subject to social
- 237 desirability and recall biases. Misclassifying people as exposed, either where people do not take
- drugs as prescribed or fail to disclose the drugs prescribed, would weaken effect estimates. Similarly,
- 239 electronic records often only include outcomes resulting in hospitalisation and may also be subject
- to misclassification bias.
- 241 Some studies had low precision due to small sample sizes, which affects interpretation of effect
- estimates, especially for less common microvascular complications, as well as for the investigation of
- 243 differences by drug subtypes.
- Finally, in anticipation of limited evidence, we included cross-sectional studies in our review. It is
- 245 however possible that diabetes complications increase the risk of a person developing mental illness,
- such as depression [36], and in turn the likelihood of being prescribed antidepressant or
- antipsychotic medications.

# 248 **4.2** Interpretation of findings: antidepressants

249	Our findings on antidepressant use and reduced risk of cardiovascular morbidity or mortality in
250	people with diabetes contrasts with previous reviews which report the opposite in general
251	populations that included people with and without diabetes [9, 42]. These contrasting findings may
252	reflect key differences in associations for different population sub-groups. Indeed, pooled results of
253	only studies including people with, or at high risk of, cardiovascular disease similarly found that
254	antidepressant use/prescribing was associated with a statistically non-significant reduced risk of
255	cardiovascular morbidity [42]. Systematic reviews of trials suggest that SSRI use can improve short-
256	term glycaemic control in people with diabetes [13, 14]. Some of the observational studies we
257	identified found similar results but others found no differences in glycaemic control between groups,
258	perhaps related to study population, design, sample size and approaches to control of confounding.
259	4.3 Interpretation of findings: antipsychotics
260	Our review revealed the sparse evidence on antipsychotic prescribing and diabetes outcomes.
261	Although based on just one cohort study [24], the association between antipsychotic prescribing and
262	lower mortality risk in people with schizophrenia and diabetes aligns with findings on antipsychotic
263	use and lower long-term mortality in people with schizophrenia [43, 44] and short-term mortality in
264	the general population [45]. However, in contrast to previous reports of a link between antipsychotic
265	use and increased risk of cardiovascular disease in general populations [10, 46], this cohort study
266	found the opposite. Although counter-intuitive, given their adverse metabolic and cardiovascular
267	effects [8, 34, 47], antipsychotic use alongside psychological support in people with SMI may
268	improve physical and psychosocial functioning, thereby improving lifestyle and compliance with
269	diabetes care and treatment, which in turn could reduce risk of diabetes complications The few
270	studies on antipsychotic prescribing suggest an association with increased risk of poorer glycaemic
271	control, which aligns with established adverse glycaemic effects of some antipsychotics [48].
272	4.4 Implications

273	The sparse existing literature on the association between antidepressant and antipsychotic
274	prescribing and diabetes outcomes limits our conclusions and implications for practice. There are
275	major gaps that should be addressed in future research in order to inform clinical practice. The
276	increased use of antidepressant and antipsychotic medications in the general population is
277	concerning given the evident lack of understanding of potential for adverse effects and increasing
278	prevalence of diabetes. The striking gap in the evidence on antipsychotic drug prescribing in relation
279	to diabetes outcomes in particular should be urgently addressed. Antidepressant and antipsychotic
280	drugs are an essential component of the treatment of mental health conditions, and timely
281	treatment in people with diabetes is crucial, given the poor diabetes outcomes for people with both
282	diabetes and mental ill health [49]. It is therefore important to establish treatment-associated risks
283	of diabetes outcomes within population sub-groups to inform and enhance drug prescribing and
284	monitoring practices for diabetes and its complications. To improve upon existing studies and
285	advance our understanding, future studies should: be well-powered (particularly to investigate
286	differences); include information on mental illness, lifestyle, and other confounding factors;
287	distinguish between drug subtypes; assess whether and how risk changes over time; and consider
288	the potential effects of cumulative exposures.
289	4.5 Conclusions
290	Few studies have described the association between antidepressant and antipsychotic medications
291	and diabetes outcomes, with shortcomings and mixed findings limiting the ability to draw
292	conclusions. While future research addresses this evidence gap, clinicians, including diabetologists,
293	primary care practitioners, and where appropriate, psychiatrists, should attempt to ensure regular
294	monitoring of cardiometabolic risk factors and early indicators of complications in people with
295	diabetes who are being treated with antidepressant or antipsychotic medication (irrespective of
296	indication).
• • -	

## Funding

None of the authors or their institutions received any payments or services in the past 36 months

from a third party that could be perceived to influence, or give the appearance of potentially

influencing, the submitted work.

Conflict of interest: None. None of the authors or their institutions at any time received payment or

services from a third party for any aspect of the submitted work.

#### REFERENCES

- [1] National Institute for Health and Care Excellence. BNF treatment summary: Antidepressant drugs [Internet]. 2021 [cited 2022 Nov]. Available from: https://bnf.nice.org.uk/treatmentsummary/antidepressant-drugs.html
- [2] National Institute for Health and Care Excellence. BNF treatment summary: Psychoses and related disorders [Internet]. 2021 [cited 2022 Nov Jan]. Available from: https://bnf.nice.org.uk/treatment-summary/psychoses-and-related-disorders.html
- [3] Hafferty JD, Wigmore EM, Howard DM, Adams MJ, Clarke TK, Campbell AI, et al. Pharmacoepidemiology of antidepressant exposure in a UK cohort record-linkage study. J. Psychopharmacol. 2019;33:482-93.
- [4] Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, et al. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur Neuropsychopharmacol. 2017;27:1064-76.
- [5] Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N, et al. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends. Curr Pharml Des. 2015;21:3280-97.
- [6] Wong J, Motulsky A, Abrahamowicz M, Eguale T, Buckeridge DL, Tamblyn R. Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ. 2017;356:j603.
- [7] Barnard K, Peveler RC, Holt RI. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes care. 2013;36:3337-45.
- [8] Rognoni C, Bertolani A, Jommi C. Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. Clin Drug Investig. 2021;41:303-19.

- [9] Biffi A, Scotti L, Corrao G. Use of antidepressants and the risk of cardiovascular and cerebrovascular disease: a meta-analysis of observational studies. Eur J Clin Pharmacol. 2017;73:487-97.
- [10] Zivkovic S, Koh CH, Kaza N, Jackson CA. Antipsychotic drug use and risk of stroke and myocardial infarction: a systematic review and meta-analysis. BMC Psych. 2019;19:189.
- [11] Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World Psychiatry. 2016;15:166-74.
- [12] National Institute for Health and Care Excellence. BNF treatment summary: Neuropathic pain. 2021 [cited 2022 Nov]. Available from: https://bnf.nice.org.uk/treatment-summary/neuropathicpain.html
- [13] Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in patients with diabetes mellitus and depression. The Cochrane database Sys Rev. 2012;12:Cd008381.
- [14] Roopan S, Larsen ER. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatrica. 2017;29:127-39.
- [15] Wells G, Shea B, O'Connell D, Robertson J, Peterson J, Welch V. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2022 Nov]. http://www.evidencebasedpublichealth.de/download/Newcastle\_Ottowa\_Scale\_Pope\_Bruce.pd f
- [16] Brieler J, Salas J, Scherrer J. Achievement of glycemic control and antidepressant medication use in comorbid depression and type II diabetes. Annals Family Medicine. 2022;20.
- [17] Chen AC, Huang KL, Chen HM, Chen PC, Chen VC, Chiu WC. Antidepressants and the risk of myocardial infarction among patients with diabetes: A population-based cohort study. Journal of Affective Disorders. 2021;294:109-14.

- [18] Chen KH, Wang TY, Lee CP, Yang YH, McIntyre RS, Subramaniapillai M, et al. Association between selective serotonin reuptake inhibitor and risk of peripheral artery disease in diabetes mellitus: Propensity score matching and landmark analysis. Medicine. 2022;101:e29202.
- [19] Hazuda HP, Gaussoin SA, Wing RR, Yanovski SZ, Johnson KC, Coday M, et al. Long-term Association of Depression Symptoms and Antidepressant Medication Use With Incident Cardiovascular Events in the Look AHEAD (Action for Health in Diabetes) Clinical Trial of Weight Loss in Type 2 Diabetes. Diabetes Care. 2019;42:910-8.
- [20] Rådholm K, Wiréhn AB, Chalmers J, Östgren CJ. Use of antidiabetic and antidepressant drugs is associated with increased risk of myocardial infarction: a nationwide register study. Diabetic Medicine. 2016;33:218-23.
- [21] Rohde C, Knudsen JS, Schmitz N, Østergaard SD, Thomsen RW. The impact of hospital-diagnosed depression or use of antidepressants on treatment initiation, adherence and HbA(1c)/LDL target achievement in newly diagnosed type 2 diabetes. Diabetologia. 2021;64:361-74.
- [22] Rubin RR, Peyrot M, Gaussoin SA, Espeland MA, Williamson D, Faulconbridge LF, et al. Four-year analysis of cardiovascular disease risk factors, depression symptoms, and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetes Care. 2013;36:1088-94.
- [23] Spoelstra JA, Stolk RP, Cohen D, Klungel OH, Erkens JA, Leufkens HG, et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. Journal Clin Psych. 2004;65:674-8.
- [24] Wu CS, Gau SS. Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus. Schizophrenia Bulletin. 2016;42:703-11.
- [25] Wu CS, Hsu LY, Pan YJ, Wang SH. Associations Between Antidepressant Use and Advanced Diabetes Outcomes in Patients with Depression and Diabetes Mellitus. J Clin Endocrinol Metab. 2021;106:e5136-e46.

- [26] Würtz M, Schmidt M, Grove EL, Horváth-Puhó E, Christiansen CF, Sørensen HT. Preadmission use of selective serotonin reuptake inhibitors and short-term mortality in diabetic patients hospitalized due to stroke. J Int Med. 2016;280:407-18.
- [27] Rohde C, Thomsen RW, Østergaard SD. A Within-Subject Before-After Study of the Impact of Antidepressants on Hemoglobin A1c and Low-Density Lipoprotein Levels in Type 2 Diabetes. J clin psychopharmacol. 2022;42:125-32.
- [28] Lipscombe LL, Lévesque L, Gruneir A, Fischer HD, Juurlink DN, Gill SS, et al. Antipsychotic drugs and hyperglycemia in older patients with diabetes. Archives of Internal Medicine. 2009;169:1282-9.
- [29] Noordam R, Aarts N, Peeters RP, Hofman A, Stricker BH, Visser LE. Selective Serotonin Reuptake Inhibitors Decrease Pancreatic Insulin Secretion in Older Adults and Increase the Risk of Insulin Dependence in Type 2 Diabetes Patients. The Journal of clinical psychiatry. 2016;77:e1124-e9.
- [30] Higgins TS, Jr., Ritchie CS, Stetson BA, Burke JD, Looney SW. An examination of the moderating effect of treatment with anti-depressants on the association of heart disease with depression in males with type 2 diabetes attending a Veterans Affairs Medical Center. Diabetes Res Clin Prac. 2007;75:220-8.
- [31] Kammer JR, Hosler AS, Leckman-Westin E, DiRienzo G, Osborn CY. The association between antidepressant use and glycemic control in the Southern Community Cohort Study (SCCS). Journal Diabetes complicat. 2016;30:242-7.
- [32] Wake DJ, Broughton P, Perera SM, MacIntyre DJ, Leese GP. Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study. Psychoneuroendocrinology. 2016;66:214-20.
- [33] Yekta Z, Xie D, Bogner HR, Weber DR, Zhang X, Harhay M, et al. The association of antidepressant medications and diabetic retinopathy among people with diabetes. Journal Diabetes complicat. 2015;29:1077-84.

- [34] Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PloS One. 2014;9:e94112.
- [35] Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up: population based cohort study. BMJ. 2018;361:k1951.
- [36] Nouwen A, Adriaanse MC, van Dam K, Iversen MM, Viechtbauer W, Peyrot M, et al. Longitudinal associations between depression and diabetes complications: a systematic review and metaanalysis. Diabetic Medicine. 2019;36:1562-72.
- [37] Vinogradova Y, Coupland C, Hippisley-Cox J, Whyte S, Penny C. Effects of severe mental illness on survival of people with diabetes. BJPsych. 2010;197:272-7.
- [38] Wu CS, Lai MS, Gau SS. Complications and mortality in patients with schizophrenia and diabetes: population-based cohort study. BJPsych. 2015;207:450-7.
- [39] M DEH, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52-77.
- [40] Scheuer SH, Fleetwood KJ, Licence KAM, Mercer SW, Smith DJ, Sudlow CLM, et al. Severe mental illness and quality of care for type 2 diabetes: A retrospective population-based cohort study. Diabetes Res Clin Prac. 2022;190:110026.
- [41] Kontopantelis E, Olier I, Planner C, Reeves D, Ashcroft DM, Gask L, et al. Primary care consultation rates among people with and without severe mental illness: a UK cohort study using the Clinical Practice Research Datalink. BMJ Open. 2015;5:e008650.
- [42] Maslej MM, Bolker BM, Russell MJ, Eaton K, Durisko Z, Hollon SD, et al. The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis. Psychotherapy and psychosomatics. 2017;86:268-82.
- [43] Taipale H, Tanskanen A, Mehtälä J, Vattulainen P, Correll CU, Tiihonen J. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry. 2020;19:61-8.

- [44] Vermeulen J, van Rooijen G, Doedens P, Numminen E, van Tricht M, de Haan L. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017;47:2217-28.
- [45] Schneider-Thoma J, Efthimiou O, Huhn M, Krause M, Reichelt L, Röder H, et al. Secondgeneration antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. Lancet Psychiat. 2018;5:653-63.
- [46] Huang KL, Fang CJ, Hsu CC, Wu SI, Juang JJ, Stewart R. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. J Psychopharmacol. 2017;31:1544-55.
- [47] Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. Ment Health Clin. 2017;7:246-54.
- [48] Whicher CA, Price HC, Holt RIG. Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and impaired glucose regulation. European J Endocrinol. 2018;178:R245-r58.
- [49] Guerrero Fernández de Alba I, Gimeno-Miguel A, Poblador-Plou B, Gimeno-Feliu LA, Ioakeim-Skoufa I, Rojo-Martínez G, et al. Association between mental health comorbidity and health outcomes in type 2 diabetes mellitus patients. Scientific reports. 2020;10:19583.

# **Figure legends**

Figure 1 Study selection flow diagram

#### Table 1: Characteristics of included studies

First author, year, study setting	Study population	Data source	Exposure definition	Total participants [exposed   not exposed] <sup>†</sup>	Mean age*, years (± SD)	Male (%)	Outcome/case definition [follow-up duration] <sup>‡</sup>
COHORT STU	IDIES						
Spoelstra, 2004 [23] Netherland s	<ul> <li>Newly diagnosed T2DM (based on oral GLDs only); 6 cities</li> <li>Exclusions: prescribed insulin within 3 months of T2DM diagnosis</li> </ul>	Outpatient pharmacy dispensing records	Any versus no AP prescription	3,001 [248   2,743]	63 (SE 0.24)	49	First insulin prescription [5 years]
Ru bin, 2010, 2013 [22] USA	<ul> <li>Overweight/obese in weight loss trial; aged 45-76 years</li> <li>Verified self-reported T2DM</li> <li>Exclusions: SMI; poor glucose control; raised cholesterol/hypertension; failed exercise test.</li> </ul>	Trial	A ny versus no AD prescription (ascertained from prescriptions brought to assessments)	5,145 [1,389   3,756]	59 (6.8)	41	Glycaemic control, insulin prescription, hypertension, dyslipidaemia [4 years]
Rådholm, 2015 [20] Sweden	<ul> <li>Aged 45-84 years with diabetes (classified by prescription of GLDs only)</li> </ul>	National registers	Any versus no AD prescription; national drug register	241,787 [43,412   198,375]	NR	NR	First fatal/non-fatal MI; national MI register [3 years]
Brieler, 2016 [16] USA	<ul> <li>Aged 18-90 years with T2DM, classified by depression &amp; AD treatment status</li> <li>Exclusions: prescribed ADs for reasons other than depression.</li> </ul>	Primary care data registry	Any versus no AD prescription	1,399 [treated depression: 225   untreated depression: 40]	62 (12.8)	41	Optimal glycaemic control [3 years]
Wu, 2016 [24] Taiwan	<ul> <li>Schizophrenia and newly diagnosed T2DM</li> <li>Exclusions: diabetes complications (pre- existing or within 6 months of diagnosis</li> </ul>	National health insurance database	Regular and irregular AP prescription versus no AP prescription	17,629 [irregular: 5,871; regular: 8,531   3,227]	47 (12.3)	49	CV morbidity, microvascular morbidity, all-cause mortality [11.5 years]
Würtz, 2016 [26] Denmark	•T1DM or T2DM and a first-ever hospitalisation for stroke	National registers (including pharmacy dispensing)	Current, new, long- term, or former SSRI prescription versus no SSRI prescription	12,620 [current: 1,432; former: 233   10,955]	< 60: 14.4% 60-69: 23.1% 70-79: 31.9% ≥ 80: 30.6%	57	Mortality (30 days following stroke) [30 days]
Hazuda, 2019 [19]	<ul> <li>Overweight/obese; aged 45-76 years with verified self-reported T2DM included in a</li> </ul>	Trial	Any versus no AD prescription	5,145 [848   4,297]	59 (6.8)	41	Composite CV outcomes [median 9.6 years]

USA	weight loss trial • Exclusions: SMI, poor glucose control hypertension, raised cholesterol, and failed exercise test		(prescriptions brought to annua assessment visits)				
Chen, 2021 [17] Taiwan	<ul> <li>Aged ≥50 years; diabetes diagnosed 1997-2010.</li> <li>Exclusions: incomplete data; history of MI before diabetes diagnosis; AD use of 1-27 cDDD during follow-up</li> <li>Created two cohorts: one based on total diabetes population and a matched cohort</li> </ul>	National health insurance database	AD use of >180 days versus no use and cumulative AD use ≥28 cDDD versus no AD use	500,990 [162,057   338,933]	50-59: 43% 60-69: 37% 70-79: 17% ≥80: 3%	51	First inpatient recorded diagnosis of MI
Rohde, 2021 [21] Denmark	<ul> <li>Aged ≥30 years with newly diagnosed T2DM in defined geographical area</li> </ul>	Laboratory & pharmacy dispensing datasets	Current or former AD prescription versus no AD prescription	87,650 [current: 9,963; former: 4,809   65,101]	Current AD: median 66 (IQR 55-77); no AD: median 65 (IQR 55-74)	Current AD: 42; no AD: 60	Optimal glycaemic control, first GLD prescription, LDL cholesterol [1 year]
Wu, 2021 [25] Taiwan	<ul> <li>Aged ≥20 years with depressive disorder (but not schizophrenia or bipolar disorder) &amp; incident diabetes diagnosed 2001-2014</li> <li>No complications at 6 months post-diabetes diagnosis</li> </ul>	National health insurance database	AD use defined using an adherence measure (no use, poor use, partial use, and regular use)	36,276 [NR   NR]	20-44: 27.2% 45-64: 55.6% ≥65: 17.1%	39	Macrovascular complications; microvascular complications; all-cause mortality
Chen, 2022 [18] Taiwan	<ul> <li>Aged ≥18 years; diabetes diagnosed 1999-2013</li> <li>Exclusions: record of AD use within the prior 2 years; prior PAD or venous thromboembolism or malignant neoplasm; follow-up of &lt;1 year</li> <li>Additional propensity score-matched cohort included</li> </ul>	National health insurance database	SSRI use versus no SSRI use	5049 [459   4590]	18-44: 16% 45-64: 52% ≥65: 32%	42	[median 5 years] Peripheral artery disease [14 years]
SELF-CONTRO	OLLED STUDIES						
Rohde, 2022[27] Denmark	<ul> <li>Aged ≥30 years, in defined geographical area, with T2DM diagnosed 2000-2016, without a psychotic or bipolar disorder</li> <li>No AD prescription in the 100 days prior to T2DM diagnosis &amp; redeemed a first AD prescription during follow-up</li> </ul>	Routinely collected health datasets, including clinical laboratory datasets	Comparison of outcome in the pre/post AD initiation period (index date being date of AD initiation)	14,919 initiated AD medication [NA]	Median 65 (IQR 54-75)	54%	Mean HbA1c and LDL levels [32 months; 16 months pre-index date & 16 months post-index date]

CASE-CONTR	OL STUDIES						
Lipscombe, 2009 [28] Canada	<ul> <li>Aged ≥ 66 years in defined geographical area with diabetes</li> <li>Exclusions: receiving dialysis or palliative care</li> </ul>	Regional routine databases	Current and recent past AP prescription versus remote AP prescription	13,817 [1,594 cases (current: 909; recent past: 251)   14,370 controls (current: 7,455; recent past: 3,008)	Cases, insulin: 76 (6.1); oral medication: 78 (6.6); none: 78 (7.0)	Cases, insulin: 47; oral medicat ion: 51; none: 50	Hospitalisation for hyperglycaemia [5 years]
Noordam, 2016 [29] Netherland S	• Aged $\geq$ 45 years with T2DM (classified by oral GLDs only) in a defined geographical area who agreed to participate.	Routinely collected pharmacy data	Current and past SSRI and TCA prescription versus no AD prescription	1,677 [304 cases (current SSRI: 9; past SSRI: 32; current TCA: 8; past TCA: 40)   controls unclear]	72 (9.7)	44	First insulin prescription [NR]
CROSS-SECTI	ONAL STUDIES						
Higgins, 2007 [30] USA	<ul> <li>Men aged ≥40 years with T2DM, visiting a veterans treatment centre</li> <li>Exclusions: prescribed ADs for neuropathy</li> </ul>	Survey	Any versus no AD prescription (treatment centre electronic records)	8,185 [1,598   6,587]	Depression: > 60: 43%; No depression: > 60: 70%	100	CVD (through treatment centre electronic records)
Yekta, 2015 [33] USA	<ul> <li>Aged 40-85 years with self-reported T2DM or HbA1c values ≥ 6.5%/48 mmol/mol.</li> <li>Exclusions: prescribed insulin at diagnosis or blindness, eye infections, eye patches, or immunological disorders</li> </ul>	Annual national survey	Any versus no AD prescription; self- report in interviews	1,144 [186   958]	Median 64	48	Retinopathy (retinal imaging assessed by experienced graders)
Kammer, 2016 [31] USA	<ul> <li>Aged 40-79 years with self-reported T1DM and T2DM, attending community health clinics in low-income areas</li> <li>Exclusions: did not provide a blood sample or sickle cell anaemia</li> </ul>	Survey	SSRI, SNRI, TCA, other AD, or multiple AD prescription versus no AD prescription; self- report in interviews	462 [92   370]	40-49: 40% 50-65: 48% >65: 12%	14	HbA1c (standardised measurements following interview)
Wake, 2016 [32] Scotland	• People with T1DM and T2DM	National diabetes register	Any versus no AP prescription	25,982 <sup>¶</sup> [2,362   23,620] <sup>¶</sup>	64	NR	Retinopathy, HbA1c, systolic and diastolic blood pressure and cholesterol

\*Mean age and standard deviation where reported unless otherwise stated

<sup>†</sup>Gives the number of people in the exposed (AD or AP) and unexposed (AD or AP) groups, with more detailed subgroups or cases and controls specified where applicable

<sup>\*</sup>Maximum follow-up time unless otherwise stated

<sup>1</sup>Exposed patients matched 1:10 to unexposed controls; total number of participants and number of participants unexposed deduced from this

AD: antidepressant; AP: antipsychotic; CHD: CV: cardiovascular; CVD cardiovascular disease; GLD: glucose lowering drug; HbA1c: glycated haemoglobin; IQR: interquartile range; LDL: lowdensity lipoprotein; MI: myocardial infarction; NR: not reported; SD: standard deviation; SE: standard error; SMI: severe mental illness; SNRI: selective norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; T1DM/T2DM: type 1/type 2 diabetes mellitus; TC: total cholesterol; TCA: tricyclic antidepressant

First				Re	Results			
author, year	Statistical methods Outcome		Reference	Antidepressant prescription	Effect estimate (CI)*	Direction of association <sup>†</sup>		
COHORT ST	UDIES							
Rubin, 2010, 2013 <sup>‡[22]</sup>	GEE	Sub-optimal glycaemic control <sup>¶</sup> or insulin prescription	No AD	AD in prior year	OR 1.13 (0.96-1.32)	$\leftrightarrow$		
Rådholm, 2015 [20]	Descriptive	First fatal or non-fatal Ml	No AD	AD (2 year run-in)	<i>Men, 45-64 years</i> : 7.6 vs 6.0 per 1,000 years <i>Women, 45-64 years</i> : 5.4 vs 3.7 per 1,000 years <i>Men, 65-84 years</i> : 16.2 vs 12.6 per 1,000 years <i>Women, 65-84 years</i> : 13.3 vs 10.3 per 1,000 years	ተ <sup>\$</sup> ተ <sup>\$</sup> ተ <sup>\$</sup> ተ <sup>\$</sup>		
Brieler, 2016 [16]	GEE	Optimal glycaemic control <sup>¶</sup>	Depression with no AD	Depression with AD (4 year observation)	OR 1.95 (1.02-3.71)	↓(of sub-optima g ycaemic control)		
Würtz, 2016 [26]	Cox proportional hazards	Mortality (30 days following stroke)	No SSRI	Current SSRI (any) New SSRI Long-term SSRI Former SSRI	Rate ratio 1.3 (1.1-1.5) Rate ratio 1.5 (1.2-1.8) Rate ratio 1.2 (1.1-1.4) Rate ratio 1.3 (1.0-1.7)	$\uparrow \\ \uparrow \\ \leftrightarrow$		
Hazuda,	Сох	Composite: mortality	No AD	Baseline AD**	<i>Men:</i> HR 0.95 (0.71-1.27)	$\leftrightarrow$		
2019 <sup>#</sup> [19]	proportional hazards	and CVD			Women: HR 0.71 (0.53-0.95)	$\checkmark$		
Chen, 2021[17]	Cox proportional hazards (of matched cohort)	First MI	No AD	No AD	HR 0.68 (0.66-0.71)	Ŷ		
Rohde, 2021 [21]	Cox proportional hazards	Optimal glycaemic control <sup>¶</sup>	No AD	Current AD Former AD	OR 0.99 (0.93-1.06) <b>OR 1.07 (1.01-1.14)</b>	↔ ↓ (of sub- optimal glycaemic control)		

Table 2: Results of observational studies reporting on the association between antidepressant drug prescribing and outcomes in people with diabetes

		GLD prescription No AD		Current AD	OR 1.39 (1.34-1.44)	$\uparrow$
		(including insulin)		Former AD	OR 1.35 (1.31-1.40)	$\uparrow$
Wu, 2021	None	Incidence of diabetes	No AD	Macro complications	69.2 versus 65.6 per 1000 person-years	↑ <sup>§</sup>
[25]		complications & all-		Micro complications	42.4 versus 40.9 per 1000 person-years	$^{ m s}$
		cause mortality		All-cause mortality	19.8 versus 17.3 per 1000 person-years	$\uparrow^{\$}$
Chen 2022 [18]	Cox proportional hazards	PAD	No SSRI	SSRI	HR 1.13 (0.76-1.69)	$\leftrightarrow$
SELF-CONTR	OLLED STUDIES					
Rhode,	Mean percent	Mean HbA1c	Pre post A D	initiation comparison	-0.16% (95% Cl, -0.18%0.13%)	$\downarrow$
2022 [27]	change	Weath HDATC	FTE-post AD		Age-sex reference population:	
2022 [27]	enunge				-0.03% (95% Cl, -0.04%0.01%)	$\checkmark$
		Mean LDL	Pre post A D	initiation comparison	-0.17% (95% Cl, -0.19%0.15%)	$\downarrow$
			FTE-post AD		Age-sex reference population:	
					-0.15% (95% Cl, -0.16%0.13%)	$\downarrow$
CASE-CONTR	ROL STUDIES					
Noordam,	Conditional	Insulin prescription	No AD	Current SSRI (any)	HR 1.81 (0.89-3.71)	$\leftrightarrow$
2016 [29]	logistic			Current TCA (any)	HR 1.40 (0.67-2.96)	$\leftrightarrow$
	regression			Current SSRI (>90 days)	HR 2.17 (1.02-4.60)	$\uparrow$
				Current TCA (>90 days)	HR 1.90 (0.89-4.06)	$\leftrightarrow$
				Past SSRI	HR 0.99 (0.65-1.51)	$\leftrightarrow$
				Past TCA	HR 0.94 (0.65-1.38)	$\leftrightarrow$
CRUSS-SECT	IONAL STUDIES					
Higgins,	Logistic	Composite: CVD	No AD	AD	OR 1.19 (Cl not available, P = 0.005)	$\uparrow$
2007 [30]	regression	M	No AD	AD	OR 1.27 (Cl not available, P = 0.011)	$\uparrow$
Yekta,	Logistic	Retinopathy	No AD	AD	OR 0.48 (0.24-0.95)	$\checkmark$
2015 [33]	regression				Without depression: OR 0.61 (0.07-5.20)	$\leftrightarrow$
					With depression: OR 0.41 (0.24-0.70)	$\downarrow$
Kammer,	Linear	Log HbA1c	No AD	SSRI	-0.03 (SE 0.04)	$\leftrightarrow$
2016 [31]	regression			SNR	-0.05 (SE 0.11)	$\leftrightarrow$
				ТСА	-0.08 (SE 0.11)	$\leftrightarrow$
				Other	0.03 (SE 0.10)	$\leftrightarrow$

Multiple

0.12 (SE 0.09)\*\*

 $\uparrow$ 

\* Results given for fully adjusted or matched models unless otherwise stated (full details of factors adjusted for given in supplementary table 4); estimates in bold are statistically significant at the P < 0.05 level)

Denotes significant P < 0.05

<sup>†</sup>↑ = increased risk of outcome; ↓= decreased risk of outcome; ↔ = no association (with statistical significance at the P < 0.05 level, unless otherwise stated)

<sup>+</sup> Results given for the control arm (diabetes support and education) of the clinical trial from which the cohort is derived

<sup>¶</sup> Hba1C < 7%/53 mmol/mol

<sup>§</sup>Statistical comparisons not presented; significance not given

<sup>#</sup> Results given for the primary outcome

\*\*Authors state that similar results were obtained where analysing AD prescribing as a time-varying covariate (not reported)

<sup>++</sup>Standardised effect estimate 0.12 reported to translate into a HbA1c effect of 1.26%/13.8 mmol/mol

AD: antidepressant; AP: antipsychotic; BMI: body mass index; CCI: Charlson Comorbidity Index; CI: confidence interval; CV: cardiovascular; CVD: cardiovascular disease; GEE: Generalised estimating equations; GLD: glucose lowering drug; HbA1c: glycated haemoglobin; HR: hazard ratio; HRT: hormone replacement therapy; LDL: low-density lipoprotein; MI: myocardial infarction; OR: odds ratio; SBP: systolic blood pressure; SE: standard error; SNRI: serotonin–norepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor; TCA: tricyclic antidepressant; TG: triglyceride

	Charles land	Referenc						
First author, year	Statistical methods	Outcome	Referenc e	Antipsychotic prescription	Effect estima	Direction of association <sup>‡</sup>		
COHORT STUDIES								
Spoelstra, 2004 [23]	Cox proportional hazards	Insulin prescription	ΝοΑΡ	AP within 2 years of diabetes diagnosis	2 years post diagnosis	Adjusted for age and year: HR 2.0 (1.2- 3.3)*	$\uparrow$	
						Adjusted for medication: HR 1.7 (1.0-3.0)	$\leftrightarrow$	
Wu, 2016 [24]	Cox proportional	CV morbidity	No A P	Irregular AP	HR 0.83 (0.70	-0.98)*	$\checkmark$	
	hazards <sup>¶</sup>			Regular AP	HR 0.80 (0.66-0.97)*		$\downarrow$	
		Microvascular	No A P	Irregular AP	HR 0.99 (0.81	-1.22)	$\leftrightarrow$	
		morbidity		Regular AP	HR 0.83 (0.62	-1.11)	$\leftrightarrow$	
		All-cause mortality	No A P	Irregular AP	HR 0.79 (0.69-0.90)*		$\checkmark$	
				Regular AP	HR 0.73 (0.62	-0.85)*	$\checkmark$	
CASE-CONTROL STU	IDIES							
Lipscombe, 2009	Conditional	Hospitalisation for	Remote	Current AP (any)	RR 1.50 (1.29	-1.74)	$\uparrow$	
[28]	logistic	hyperglycaemia	AP		Insulin: RR 1.40 (1.06-1.84)*		$\uparrow$	
	regression					1.36 (1.12-1.66)*	$\uparrow$	
					None: RR 2.4		$\uparrow$	
				Current AP (first time)	Insulin: RR 15.4 (8.12-29.2)*		$\uparrow$	
						14.4 (8.71-23.8)*	1	
					None: RR 8.9	· ·	$\uparrow$	
				Current AP (prevalent)		36 (1.03-1.79)*	<b>↑</b>	
						1.31 (1.08-1.60)*	↑ ♠	
						3 (1.48-3.37)*	↑ ()	
				Recent past AP	Insulin: RR 0.8		$\leftrightarrow$	
					None: RR 1.3	1.04 (0.80-1.34)	$\leftrightarrow \\ \leftrightarrow$	
CROSS-SECTIONAL	STUDIES				WUILE. NN 1.3.	L (0.70-2.27)	$\leftarrow$	
Wake, 2016 [32]	Student's t	Mean HbA1c		onths in total)	55.1 ± 2.3*		$\checkmark$	
	test/chi-squared	(mmol/mol) ± SD	No A P		58.2 ± 1.3			
	test	Retinopathy	AP (≥12 m	onths in total)	28*		$\downarrow$	
		(prevalence, %)	No A P		32			

Table 3: Results of observational studies reporting on the association between antipsychotic drug prescribing and outcomes in people with diabetes

\*Denotes significant P < 0.05

<sup>t</sup>Results given for fully adjusted or matched models unless otherwise stated (full details of factors adjusted for given in supplementary table 4)

 $^{\dagger}$   $\uparrow$  = increased risk of outcome;  $\downarrow$  = decreased risk of outcome;  $\leftrightarrow$  = no association (with statistical significance at the P < 0.05 level, unless otherwise stated)

<sup>¶</sup>Time-dependent with AP prescribing measured in 6 month intervals

AD: antidepressant; AP: antipsychotic; BMI: body mass index; CCI: Charlson Comorbidity Index; CI: confidence interval; CV: cardiovascular; GLD: glucose lowering drug; HbA1c: glycated haemoglobin; HR: hazard ratio; SD: standard deviation; RR: rate ratio

